Full-Time

Vice President of Clinical Development Operations

Strand Therapeutics

Strand Therapeutics

51-200 employees

Develops programmable, long-acting mRNA therapeutics

Compensation Overview

$316k - $356k/yr

+ Bonus + Equity Incentives

Boston, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • 15+ years of clinical trial operations experience in biotech; experience working in a smaller, fast paced environment highly preferred with 5+ in management or leadership roles
  • Experience running oncology trials required
  • Experience in and understanding of end-to-end management of clinical trial conduct, the pharmaceutical industry, clinical drug development, clinical trials operations and regulatory components is essential
  • Experience with all aspects of clinical trial management including streamlining operational activities of trial protocols and ensuring deliverables are attained in a timely manner
  • Proven success participating in cross-departmental clinical strategy, planning and implementation activities (Departments include executive leadership, regulatory, QA, CMC, translational development, program management, finance, business development, medical affairs and medical writing)
  • Extensive experience with the identification, negotiation, management, and oversight of external vendor partnerships, such as CROs, for monitoring, database management, statistics, and safety reporting
  • Experience building an internal clinical program management function, managing a team of employees and consultants as well as hiring internal stakeholders to support trial needs and leveraging external consultants as needed
  • Experience with regulatory submissions, including INDs, NDAs and BLAs highly preferred
  • Experience interacting with domestic health authorities, such as the FDA, required; Experience interacting with global regulatory health authorities, such as the EMA, PMDA, and/or Australian CTN is a plus
  • Strong interpersonal skills with the ability to interact and communicate effectively with individuals from multiple departments at all levels of the organization
  • Strong organizational and time management skills
Responsibilities
  • Serve as the clinical operations expert for all clinical stage and preclinical stage programs for the company
  • Accountable for delivery of assigned clinical program/trial budgets, managing study timelines, and resource management with focus on quality, including making recommendations and decisions regarding operational strategies to support study and/or program objectives
  • Develop operational strategy and clinical operations plans in support of execution of the Clinical Development Plan
  • Develop clinical timelines, budget forecasts and ensure accountability for tracking and deliverables
  • Develop and maintain departmental resource and budget plans
  • Ensures oversight and study-specific Risk Management Plans (RMP) (e.g., milestones, metrics, and critical path), ensuring appropriate escalation when required. Evaluate study-level issues for broader impact (e.g., cross-study, cross-program etc.) and ensure resolution
  • Partner and collaborate with cross-functional stakeholders, external consultants, and other relevant stakeholders
  • Lead and oversee execution of clinical trials in compliance with ICH/GCP, local regulations, and Strand Therapeutics’ SOPs to ensure quality and data integrity
  • Support the selection, oversight, and management of CROs and other vendors including financial aspects of the partnerships
  • Oversee site feasibility/capability assessments in collaboration with the CRO and cross-functional team
  • Develops site recruitment, enrollment, and engagement strategies for all clinical trials
  • Review and provide clinical operations input into relevant clinical documents such as the protocol, investigator brochure, regulatory documents, clinical study reports and other documents and plans as appropriate
  • Manage and provide oversight to the cross functional teams and CRO/vendor(s) related to all aspects of clinical trial operations
  • Responsible for representing Clinical Operations on cross-functional project teams and vendor/CRO operational meetings and ensuring compliance with operational standards and procedures. Manages content, agenda, and discussions at clinical operations sub-teams and ensures action items are closed
  • Along with other Clinical Development personnel, represent Strand Therapeutics externally to Investigators, site staff, and Key Opinion Leaders
  • Perform and document study level Sponsor Oversight of outsourced clinical activities
  • Communicate study-status, cost, and issues to ensure timely decision-making by senior management
  • Oversee/collaborate with Clinical Quality Assurance on and contribute to inspection readiness activities that support audits and regulatory inspections related to clinical trial conduct
  • Maintain oversight and participate in the creation/review/training/maintenance of departmental and organizational SOPs to ensure compliance
  • Lead and/or participate in clinical operations workstreams related to departmental and operating model related initiatives
  • Develop and foster strong, collaborative relationships with key stakeholders both within and external to Strand Therapeutics
  • Provide oversight and mentorship to assigned Clinical Operations staff by providing clinical operations/functional area expertise and support identification and prioritization of study and program level work. Will have direct line management of Clinical Operations staff
  • Strive for continuous improvement and more efficient ways of working in clinical operations
  • Supervise Clinical Operations Team (CTMs, CRAs, CTAs, etc.) and ensure team member’s adherence to the regulatory requirements, ICH-GCP guidelines, and other relevant procedures
  • Participate in the design, development and review of clinical trial protocols and study-specific documents, e.g., informed consent forms, study guidelines, operations manuals, oversight plans, process developments (including Trial RACI)
  • Keep up to date with industry practice and communicate key messages back to Strand Therapeutics, providing recommendation accordingly
Desired Qualifications
  • Experience with INDs, NDAs and BLAs highly preferred
  • Experience interacting with global regulatory health authorities, such as the EMA, PMDA, and/or Australian CTN is a plus

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company Size

51-200

Company Stage

Series B

Total Funding

$256M

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • STX-001 Phase 1 showed confirmed complete response and partial responses by April 2025.
  • $153M Series B from Regeneron, Lilly, Amgen funds STX-003 Phase 1 in 2026.
  • New CFO Kunal Bhatia and CMO Jason Luke strengthen leadership for Phase 2 transition.

What critics are saying

  • Regeneron's liblocalcin achieves 62% ORR in refractory melanoma, eroding STX-001 edge.
  • FDA clinical hold on self-replicating RNA like Gritstone's halts STX-001 by Q2 2026.
  • Eli Lilly enforces milestone repayment if STX-001 misses 20% ORR in Q4 2026 readout.

What makes Strand Therapeutics unique

  • STX-001 deploys programmable mRNA with logic circuits sensing diseased cells only.
  • Intratumoral STX-001 produces localized IL-12, activating immunity without systemic toxicity.
  • Platform enables cell-type specific, multi-functional mRNA therapies for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Strand Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Phone/Internet Stipend

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
The Pharma Data
Aug 23rd, 2025
Strand Therapeutics Names Dr. Jason J. Luke as New Chief Medical Officer

Strand Therapeutics strengthens leadership with appointment of Dr. Jason J. Luke as Chief Medical Officer.

BiopharmaTrend
Aug 11th, 2025
Strand Therapeutics Secures $153 Million for Programmable mRNA Cancer Therapies

Kinnevik's Ala Alenazi, Ph.D., will join Strand's board of directors.

Crunchbase
Aug 8th, 2025
The Week's 10 Biggest Funding Rounds: Public Safety Leads, While Healthcare And Fintech Also See Big Deals

Strand Therapeutics, $153M, biotechnology: Boston-based Strand Therapeutics, a developer of mRNA-based therapeutics, raised $153 million in a Series B funding led by Kinnevik.

Business Wire
Aug 8th, 2025
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.

BioSpace
Aug 7th, 2025
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds

Strand Therapeutics on Thursday closed a $153 million series B round that will help it advance its pipeline of novel mRNA therapies for cancer and other chronic conditions.